InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Presents Phase 3 SAD Study Results at ASCP Annual Meeting
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has reported the results of its phase 3 open-label study of fasedienol (“PH94B”) nasal spray for the treatment of adults with social anxiety disorder (“SAD”). The company presented the results during at the 2023 annual meeting for…